CORRIXR THERAPEUTICS Trademark

Trademark Overview


On Thursday, March 31, 2022, a trademark application was filed for CORRIXR THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the CORRIXR THERAPEUTICS trademark a serial number of 97340109. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, October 10, 2023. This trademark is owned by CorriXR Therapeutics, Inc.. The CORRIXR THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development; research and development of therapeutics pharmaceuticals using gene editing; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy
corrixr therapeutics

General Information


Serial Number97340109
Word MarkCORRIXR THERAPEUTICS
Filing DateThursday, March 31, 2022
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, October 10, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 15, 2023

Trademark Statements


Disclaimer with Predetermined Text"THERAPEUTICS"
Goods and ServicesGene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development; research and development of therapeutics pharmaceuticals using gene editing; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, April 5, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCorriXR Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNewark, DE 19713

Party NameCorriXR Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWilmington, DE 19801

Trademark Events


Event DateEvent Description
Thursday, April 11, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, April 2, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, October 10, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 15, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 15, 2023PUBLISHED FOR OPPOSITION
Wednesday, July 26, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, July 10, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, July 7, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, July 7, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 7, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 20, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, April 20, 2023NON-FINAL ACTION E-MAILED
Thursday, April 20, 2023NON-FINAL ACTION WRITTEN
Thursday, April 20, 2023PREVIOUS ALLOWANCE COUNT WITHDRAWN
Tuesday, April 18, 2023WITHDRAWN FROM PUB - OG REVIEW QUERY
Tuesday, April 4, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, April 3, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 3, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 3, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 18, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 18, 2023NON-FINAL ACTION E-MAILED
Wednesday, January 18, 2023NON-FINAL ACTION WRITTEN
Wednesday, January 18, 2023ASSIGNED TO EXAMINER
Tuesday, April 5, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, April 4, 2022NEW APPLICATION ENTERED